Pediatric Praziquantel Consortium

The Pediatric Praziquantel Consortium marks World Health Day

07 April 2020

Today is World Health Day – a global health awareness day celebrated each year on 7 April under the auspices of the...

Pediatric Praziquantel Consortium: Successful annual Access meeting

30 March 2020

Last month, ahead of the COVID-19 crisis in Europe, the Pediatric Praziquantel Consortium Access team gathered in...

A new formulation to fight Schistosomiasis


A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

The consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development and registration and access.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more